Rubius Therapeutics (RUBY) News Today → A new way to collect income from stocks (From DTI) (Ad) Free RUBY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share HeadlinesStock AnalysisInsider TradesSocial MediaSustainabilityStock AnalysisInsider TradesSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'bizjournals.com - March 11 at 5:07 PMRubius Therapeutics Inc RUBYmorningstar.com - November 5 at 8:39 PMRUBY - Rubius Therapeutics, Inc.uk.finance.yahoo.com - August 2 at 2:37 AMNorth American Morning Briefing: Alphabet, -2-morningstar.com - July 25 at 7:07 AMRubius Therapeutics Outlines Dissolution Plan, After Unsuccessful Attempt On Alternativesfinance.yahoo.com - March 2 at 1:59 AMThinking about buying stock in Sorrento Therapeutics, Rubius Therapeutics, Ideanomics, SoundHound AI, or C3.ai?marketwatch.com - February 14 at 7:55 PMWhy Is Rubius Therapeutics (RUBY) Stock Up 35% Today?msn.com - February 14 at 9:54 AMThe Wrap: Ruby's moving to Congress Street, launching new French conceptyahoo.com - January 25 at 4:27 AMRuby Wax sparks concern from fans after posting video from hospital bedmirror.co.uk - January 12 at 12:51 AMRuby Wax sparks concern amongst fans with her latest appearance from a hospital bed promoting bookdailymail.co.uk - January 12 at 12:51 AMFormer Rubius CEO jumps to another Flagship spinoutfinance.yahoo.com - November 18 at 10:30 AMRubius Therapeutics lays off most of its staff, explores salefinance.yahoo.com - November 4 at 12:16 PMRubius Therapeutics Cuts Almost 85% Of Its Workforce, Starts Looking For Strategic Alternativesfinance.yahoo.com - November 3 at 1:47 PMRubius stock falls over 5% after hours on strategic review, more job cutsseekingalpha.com - November 2 at 5:41 PMRubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changesfinance.yahoo.com - November 2 at 5:41 PMRubius Therapeutics, Inc. (RUBY)finance.yahoo.com - October 28 at 1:50 AMRubius Therapeutics Increuters.com - October 10 at 3:35 PMFlagship-backed Vesalius lays off 43%bizjournals.com - September 19 at 9:45 PMRubius Therapeutics to Present at Guggenheim Nantucket Therapeutics Conferencefinance.yahoo.com - September 19 at 11:42 AMRubius Therapeutics lays off 75% of staff, looks to sell Smithfield facilitybizjournals.com - September 14 at 11:02 AMRubius Therapeutics Shifts Its Clinical Focus, Pulls Plug On Two Early-Stage Cancer Assetsfinance.yahoo.com - September 13 at 7:37 PMRubius Therapeutics scraps platform, lays off 160finance.yahoo.com - September 13 at 7:37 PMRubius stock slumps 26% as tumor trials of RTX-240, RTX-224 axed, cuts 75% workforceseekingalpha.com - September 13 at 10:15 AMRubius To Discontinue Clinical Trials Of RTX-240, RTX-224 - Quick Factsnasdaq.com - September 13 at 10:15 AMRubius Therapeutics Announces Strategic Updatefinance.yahoo.com - September 13 at 10:15 AMRubius Therapeutics to Provide Strategic Updatefinancialpost.com - September 12 at 4:40 PMMorgan Stanley Trims Rubius Therapeutics (NASDAQ:RUBY) Target Price to $1.50marketbeat.com - September 9 at 10:21 AMPeering Into Rubius Therapeutics's Recent Short Interestmsn.com - September 7 at 10:48 PMRubius Therapeutics, Inc. (RUBY) Upgraded to Buy: What Does It Mean for the Stock?finance.yahoo.com - August 11 at 6:19 PMRubius Therapeutics: Q2 Earnings Insightsmsn.com - August 9 at 10:41 AMRubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updatetmcnet.com - August 9 at 10:41 AMRubius Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - August 9 at 10:41 AMRubius Therapeutics to Announce Second Quarter 2022 Financial Resultsfinance.yahoo.com - July 26 at 1:04 PMHotSpot Therapeutics Appoints Jose Carmona to Board of Directorsfinance.yahoo.com - July 19 at 7:31 AMRubius Therapeutics Appoints Susanne Schaffert, Ph.D., to its Board of Directorsfinance.yahoo.com - July 14 at 9:37 AMRubius Therapeutics Presents Updated Data from its Type 1 Diabetes Preclinical Program at the Federation of Clinical Immunology Societies (FOCIS) 2022 Annual Meetingfinance.yahoo.com - June 22 at 9:14 AMRubius Therapeutics Inc - Stock Newsmorningstar.com - June 3 at 8:56 AMRubius Therapeutics to Present at the Jefferies Global Healthcare Conferencefinance.yahoo.com - June 1 at 4:49 PM-$0.52 Earnings Per Share Expected for Rubius Therapeutics, Inc. (NASDAQ:RUBY) This Quartermarketbeat.com - May 28 at 12:18 AMRubius Therapeutics to Present Trials in Progress Poster for the Phase 1/2 Clinical Trial of RTX-224 in Select Advanced Solid Tumors at the 2022 American Society of Clinical Oncology Annual Meetingfinance.yahoo.com - May 26 at 5:42 PMRubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directorsfinance.yahoo.com - May 24 at 10:35 AMBinance Coin Now Buys You the Greatest Amount of Rubius Therapeutics in the Past Yearnasdaq.com - May 23 at 3:53 PMEquities Analysts Offer Predictions for Rubius Therapeutics, Inc.'s Q3 2022 Earnings (NASDAQ:RUBY)marketbeat.com - May 13 at 9:07 AMRubius price target lowered at H.C. Wainwright on trial update for cellular therapyseekingalpha.com - May 11 at 6:24 PMRubius Therapeutics (NASDAQ:RUBY) Given New $8.00 Price Target at HC Wainwrightmarketbeat.com - May 11 at 7:53 AMWhat 6 Analyst Ratings Have To Say About Rubius Therapeuticsmarkets.businessinsider.com - May 10 at 8:26 PMRubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updatefinance.yahoo.com - May 10 at 10:25 AM Brokerages Expect Rubius Therapeutics, Inc. (NASDAQ:RUBY) to Post -$0.57 EPSmarketbeat.com - May 7 at 12:15 AMRubius Therapeutics to Announce First Quarter 2022 Financial Resultsfinance.yahoo.com - April 26 at 9:36 AMRubius Therapeutics up 34% after insider buyseekingalpha.com - April 25 at 1:27 PM Get Rubius Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media. Simply tap here now to subscribe and start getting "Insider Financial Advantage" RUBY Media Mentions By Week RUBY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RUBY News Sentiment▼0.000.44▲Average Medical News Sentiment RUBY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RUBY Articles This Week▼00▲RUBY Articles Average Week Get Rubius Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RUBY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Palisade Bio News Finch Therapeutics Group News Fresh Tracks Therapeutics News TRACON Pharmaceuticals News Kiromic BioPharma News Titan Pharmaceuticals News Avalon GloboCare News Creative Medical Technology News Eloxx Pharmaceuticals News Gamida Cell News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RUBY) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rubius Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
